FierceBiotech 19 mai 2026 Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
FierceBiotech 19 mai 2026 Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
FierceBiotech 19 mai 2026 Lauxera Capital Partners raises a hefty €520M for health, medtech companies
FierceBiotech 19 mai 2026 Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial
FierceBiotech 19 mai 2026 Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
FierceBiotech 18 mai 2026 Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
FierceBiotech 18 mai 2026 BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
FierceBiotech 18 mai 2026 After rare disease flop, cash-strapped Quince finds salvation in reverse merger
FierceBiotech 18 mai 2026 Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
FierceBiotech 18 mai 2026 Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
FierceBiotech 18 mai 2026 Ohio Discovery Corridor is Attracting the World’s Best in Pediatric Research. Here’s Why
FierceBiotech 18 mai 2026 Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3
FierceBiotech 18 mai 2026 Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial